Seminars in Oncology

Papers
(The TQCC of Seminars in Oncology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Clinical efficacy and security analysis of DEB-TACE combined with trans arterial infusion of carrelizumab in the therapy of advanced liver cancer75
Unlocking the therapeutic potential of polyphenols: Promising advances and future directions in pancreatic cancer treatment67
Pretreatment eosinophilia as a biomarker for adverse outcomes in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis36
Airway disorders associated with immune checkpoint inhibitor therapy: Two case reports and a systematic review32
Masthead31
Breaking barriers: Deciphering the mechanisms of Olaparib resistance in prostate cancer23
Hepatitis B Virus Reactivation in Cancer Patients Receiving Chemotherapy—A Systematic Review and Meta-Analysis22
Integrated analysis of scRNA-seq and bulk RNA-seq data identifies BHLHE40 as a key gene in pancreatic cancer progression and gemcitabine resistance21
Table of Contents20
Overexpression of CAD in stomach adenocarcinoma tissues and its clinical significance20
Deciphering the US Regulatory Framework: Comparison Between Oncology Biosimilars and Reference Biologics19
Influence of Cancer on COVID-19 Incidence, Outcomes, and Vaccine Effectiveness: A Prospective Cohort Study of U.S. Veterans19
Psoas muscle depletion correlates with poor prognosis and compromised immunity in resectable gastric cancer: A multicenter study18
Military exposures and lung cancer in United States Veterans16
Editorial Board16
Explainable machine learning and feature interpretation to predict survival outcomes in the treatment of lung cancer15
Editorial Board14
Role of neoadjuvant pembrolizumab in advanced melanoma14
Adenocarcinoma on retrorectal cystic hamartoma: An illustrative image for a very rare diagnosis13
Advancing personalized medicine in LMICs: Predictive indicators for cervical cancer immunotherapy response13
Editorial Board13
Masthead11
Prostate cancer: Evolution of multiparametric MRI PI-RADS v2.1 toward biparametric MRI S-PI-RADS11
Editorial Board11
Assessment of PSA responses and changes in the rate of tumor growth -rate with immune checkpoint inhibitors in US Veterans with prostate cancer10
Masthead10
Acute liver failure secondary to malignant infiltration: A single center experience10
The interest of therapeutic and pharmacological drug monitoring of methotrexate: A systematic review10
Masthead10
Genome editing of immune checkpoints: CRISPR-mediated PD-1 inhibition in cancer10
Editorial Board10
The effects of microbiota-derived short-chain fatty acids on T lymphocytes: From autoimmune diseases to cancer9
Lactylation in radiosensitivity regulation: Mechanistic insights and recent advances9
Impact of the COVID-19 Pandemic on the Wellbeing of International Oncology and Hematology Fellows at the Princess Margaret Cancer Center (PMCC)9
The nervous system in prostate cancer: A basic science and clinical perspective9
Breast cancer exosomes: Managing macrophage polarization and immune regulation in the tumor microenvironment9
Biomarkers and the microbiome in the detection and treatment of early-stage non-small cell lung cancer8
Mapping the epidemiology of cancer-related anemia: A systematic scoping review of global prevalence and incidence8
Hexokinases in gastrointestinal cancers: From molecular insights to therapeutic opportunities8
The challenges of selecting cancer medicines for the WHO Essential Medicines List with the elephant in the room: A path forward7
Post translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers7
Surgery for early-stage lung cancer with video-assisted thoracoscopic surgery versus open thoracotomy: A narrative review7
Screening Adherence for Second Primary Malignancies in Breast Cancer Survivors: Behaviors, Facilitators, and Barriers to Enhance Quality Care7
A narrative review of the principal glucocorticoids employed in cancer7
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population7
Editorial Board7
Barriers and facilitators to lung cancer screening and follow-up7
High tumor mutation burden mitigates the negative impact of chemotherapy history on immune checkpoint blockade therapy6
Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects6
Masthead6
outside front cover6
Recent updates on novel heterocyclic scaffolds of anticancer potential as emerging tubulin inhibitors6
Editorial Board6
MicroRNAs: From Bench to Bedside Applications as Breast Cancer Therapeutics6
Multiple myeloma: Insights into underlying mechanisms, advances in diagnostic and therapeutic modalities6
Exosomal circular RNAs as drivers of temozolomide resistance in glioblastoma: Mechanisms and implications5
Unveiling the role of RAI14 in cancer: Biological significance and translational perspectives5
Tumor tough, therapy smarter: Rethinking CAR-T for pancreatic cancer5
Advances and challenges in cancer immunotherapy: Strategies for personalized treatment5
Masthead5
Colorectal cancer in Ethiopia: Epidemiological trends, diagnostic and laboratory capacities, and challenges5
Treating advanced lung cancer in older Veterans with comorbid conditions and frailty5
1.5687379837036